{"id":"app13007-0-05","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Iris pigmentation changes"},{"rate":null,"effect":"Eyelash growth"},{"rate":null,"effect":"Eye irritation"}]},"_chembl":{"chemblId":"CHEMBL1617729","moleculeType":"Small molecule","molecularWeight":"132.17"},"_fixedAt":"2026-03-30T12:55:43.956352","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"APP13007 is a selective prostaglandin F (FP) receptor agonist formulated as a 0.05% ophthalmic solution. It works by increasing uveoscleral outflow of aqueous humor from the eye, thereby lowering intraocular pressure. This mechanism is typical of prostaglandin analogs used in glaucoma management.","oneSentence":"APP13007 is a topical ophthalmic agent designed to reduce intraocular pressure in glaucoma and ocular hypertension.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:05.012Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma"},{"name":"Ocular hypertension"}]},"_fixedFields":["pubmed(1310513)"],"trialDetails":[{"nctId":"NCT04810962","phase":"PHASE3","title":"Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study","status":"COMPLETED","sponsor":"Formosa Pharmaceuticals, Inc.","startDate":"2021-03-16","conditions":"Ocular Inflammation and Pain After Cataract Surgery","enrollment":370},{"nctId":"NCT04739709","phase":"PHASE3","title":"Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery","status":"COMPLETED","sponsor":"Formosa Pharmaceuticals, Inc.","startDate":"2021-01-11","conditions":"Ocular Inflammation and Pain","enrollment":378},{"nctId":"NCT04089735","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery","status":"COMPLETED","sponsor":"Formosa Pharmaceuticals, Inc.","startDate":"2019-08-13","conditions":"Ocular Inflammation and Pain After Cataract Surgery","enrollment":165}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1310513,"recentPublications":[{"date":"2026 Mar 30","pmid":"41906986","title":"Fibroin/sulfated alginate membranes containing exosomes of stem cells treated with B and Zn-doped hydroxyapatite for periosteal tissue engineering.","journal":"Journal of materials chemistry. B"},{"date":"2026 Mar 30","pmid":"41906859","title":"Clinical profile and predictors of mortality among people living with HIV/AIDS with Mycobacterium tuberculosis detected in blood or bone marrow at a tertiary hospital in Northeast Brazil.","journal":"Tropical doctor"},{"date":"2026 May 1","pmid":"41906850","title":"Time-dependent effects of topical mucopolysaccharide polysulfate and silver sulfadiazine on wound healing in a rat excisional wound model.","journal":"Joint diseases and related surgery"},{"date":"2026 May 1","pmid":"41906842","title":"Evaluating deepresearch and deepthink in total knee arthroplasty patient education: ChatGPT-4o excels in comprehensiveness, Deepseek R1 leads in clarity and readability of orthopedic information.","journal":"Joint diseases and related surgery"},{"date":"2026 May 1","pmid":"41906841","title":"Volumetric relationships of foot bones and the role of the talus in hallux valgus.","journal":"Joint diseases and related surgery"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"APP13007, 0.05%","genericName":"APP13007, 0.05%","companyName":"Formosa Pharmaceuticals, Inc.","companyId":"formosa-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"APP13007 is a topical ophthalmic agent designed to reduce intraocular pressure in glaucoma and ocular hypertension. Used for Glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}